POLE and lung adenocarcinoma: Liu et al. analyzed data of 513 patients with adenocarcinoma and 497 patients with squamous cell carcinoma from TCGA cohort, and the results suggested that POLE mutation is an effective biomarker of improved OS in patients with lung squamous cell carcinoma, whereas it has no effect on OS in patients with lung adenocarcinoma [56].